EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Mitochondrial transplantation as a novel therapeutic approach in idiopathic inflammatory myopathy

Jeong Yeon Kim, Young Cheol Kang, Min Jung Kim, Seon Uk Kim, Hae Rim Kang, Jeong Seon Yeo, Yujin Kim, Shin-Hye Yu, Byeongwook Song, Jung Wook Hwang, Yun-Sang Lee, Jung Woo Byun und 5 weitere

Annals of the Rheumatic Diseases · 2025-04 · 84 (4) · 609-619

DOI: 10.1016/j.ard.2024.11.005 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Annals of the Rheumatic Diseases, 2025-04. Verfasst von Jeong Yeon Kim und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Dermatomyositis, Mesenchymal Stem Cell Transplantation, Mitochondria, Myositis. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Health and Welfare, Korea Health Industry Development Institute, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aimed to investigate the efficacy of mitochondrial transplantation as a therapeutic intervention for idiopathic inflammatory myopathy (IIM). This study used a comprehensive approach, incorporating both in vitro and in vivo IIM models, and conducted a first-in-human clinical trial to assess the effectiveness and safety of mitochondria isolated from human umbilical cord mesenchymal stem cells (PN-101). METHODS: Mitochondria isolated from umbilical cord mesenchymal stem cells were designated as PN-101. The efficacy of PN-101 was assessed using myoblasts derived from patients with IIM and C2C12 mouse perforin/granzyme B-treated myoblasts as an in vitro IIM model. PN-101's effect on IIM was examined using C protein-induced myositis (CIM) mice as an in vivo model. The efficacy and safety of PN-101 were evaluated in a phase 1/2a clinical trial involving 9 adult patients with refractory polymyositis or dermatomyositis. RESULTS: The myoblasts derived from patients with IIM exhibited defects in mitochondrial function and myogenesis. PN-101 transplantation enhances muscle differentiation and mitochondrial function in IIM myoblasts. PN-101 also enhanced intracellular adenosine triphosphate content, cell viability, and myogenesis in C2C12 perforin/granzyme B-treated myoblasts. In an in vivo model, PN-101 reduced myositis severity by exhibiting anti-inflammatory effects and restoring the CIM-induced metabolic shift. In a phase 1/2a prospective clinical trial involving adult patients with refractory IIM, PN-101 demonstrated no severe adverse drug reactions and showed at least minimal improvement in the International Myositis Assessment and Clinical Studies Group (IMACS)-Total Improvement Scores (TISs) compared with baseline. CONCLUSIONS: PN-101 transplantation could serve as a novel treatment for IIM by enhancing mitochondrial repair and reducing inflammation in muscle tissues.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DermatomyositisMesenchymal Stem Cell TransplantationMitochondriaMyositisAdultAnimalsFemaleHumansMaleMiceMiddle AgedCell DifferentiationDisease Models, AnimalMesenchymal Stem CellsMuscle DevelopmentMyoblastsTreatment OutcomeMice, Inbred C57BL

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
  • Paean Biotechnology Inc, Seoul, Korea.
  • Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Hospital Boramae Medical Center, Seoul, Korea.
  • Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Korea.
  • Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Korea; Department of Biomedical Sciences, Seoul National University, Seoul, Korea.
  • Department of Rheumatology, College of Medicine, Hanyang University Hospital for Rheumatic Diseases, Hanyang University, Seoul, Korea.

Förderung

  • Ministry of Health and Welfare
  • Korea Health Industry Development Institute
  • Ministry of Education
  • Seoul National University Hospital
  • National Research Foundation of Korea

Zitieren

APA

Kim, J. Y., Kang, Y. C., Kim, M. J., Kim, S. U., Kang, H. R., Yeo, J. S., Kim, Y., Yu, S. H., Song, B., Hwang, J. W., Lee, Y. S., Byun, J. W., Yoo, D. H., Kim, H. S., Han, K., Kim, C. H., & Lee, E. Y. (2025). Mitochondrial transplantation as a novel therapeutic approach in idiopathic inflammatory myopathy. Annals of the Rheumatic Diseases, 84(4), 609-619. https://doi.org/10.1016/j.ard.2024.11.005

Vancouver

Kim JY, Kang YC, Kim MJ, Kim SU, Kang HR, Yeo JS, et al. Mitochondrial transplantation as a novel therapeutic approach in idiopathic inflammatory myopathy. Annals of the Rheumatic Diseases. 2025;84(4):609-619. doi:10.1016/j.ard.2024.11.005

BibTeX
@article{Kim2025,
  author = {Kim, Jeong Yeon and Kang, Young Cheol and Kim, Min Jung and Kim, Seon Uk and Kang, Hae Rim and Yeo, Jeong Seon and Kim, Yujin and Yu, Shin-Hye and Song, Byeongwook and Hwang, Jung Wook and Lee, Yun-Sang and Byun, Jung Woo and Yoo, Dae Hyun and Kim, Hyun Sook and Han, Kyuboem and Kim, Chun-Hyung and Lee, Eun Young},
  title = {Mitochondrial transplantation as a novel therapeutic approach in idiopathic inflammatory myopathy},
  journal = {Annals of the Rheumatic Diseases},
  year = {2025},
  volume = {84},
  number = {4},
  pages = {609--619},
  doi = {10.1016/j.ard.2024.11.005}
}
Kostenlos starten →